Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Paul D. Benn"'
Autor:
Paul D. Benn, Ying Zhang, Lesley Kahl, Thomas J. Greene, Veronica Bainbridge, Cindy Fishman, Bo Wen, Martin Gartland
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 3, Pp n/a-n/a (2023)
Abstract We report the safety and pharmacokinetic properties of the HIV‐1 maturation inhibitor GSK3739937 (GSK'937) in healthy participants. This was a phase I, first‐in‐human, double‐blind, randomized, placebo‐controlled, single‐ (part 1
Externí odkaz:
https://doaj.org/article/8a910cb4b94042ba90ad7e446d8260ac
Autor:
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy P. Moore, Ciara S. Seal, Amy G. Cutrell, Ronald D. D'Amico, Paul D. Benn, Raphael J. Landovitz, Mark A. Marzinke, William R. Spreen, Susan L. Ford
Publikováno v:
British journal of clinical pharmacology, vol 88, iss 10
AimTo characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic factors with pharmacokinetic variability.MethodsAnalyses were implemented in NONMEM and R. Co
Autor:
Thomas A. Lutz, Susan Swindells, Vasiliki Chounta, Christine L. Talarico, Jenny Huang, Lelanie van Zyl, Paul D Benn, William Spreen, Kati Vandermeulen, Kimberly Y. Smith, Herta Crauwels, Conn M. Harrington, Essack Mitha, Norma Porteiro, Susan L. Ford, Simon Vanveggel, Matthias Stoll, Kai S Hove, Rodica Van Solingen-Ristea, David A. Margolis, Alyssa Shon
Publikováno v:
AIDS (London, England)
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug dai
Autor:
Stephen Taylor, Iain Reeves, Ashini Fox, Jean van Wyk, Paul D Benn, Alistair Paice, Matthew Radford, Adam Croucher, Chinyere Okoli, Melissa Myland, Naomi J. Boxall, Sajid Munshi, Justine Barnes, Alison Darley, Achim Schwenk, Fiona Grimson
Publikováno v:
International Journal of STD & AIDS
Objectives: The objective of this study was to describe the real-world use and effectiveness of dolutegravir-based regimens (DBRs) in routine clinical practice in the United Kingdom. Methods: Retrospective analysis was conducted using data from four
Autor:
Simon Vanveggel, Kimberly Y. Smith, David A. Margolis, Krischan J Hudson, Paul D Benn, Mark S. Shaefer, Anthony Mills, Yuanyuan Wang, Rodica Van Solingen-Ristea, Susan Swindells, William Spreen, Edgar T. Overton, Vasiliki Chounta
Publikováno v:
The Patient
Background Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual’s experience of treatment an
Autor:
Miguel García Deltoro, Veerle Van Eygen, Paul D Benn, Kimberly Y. Smith, Hans Jaeger, Parul Patel, Fritz Bredeek, Rodica Van Solingen-Ristea, Christine L. Talarico, William Spreen, Marie-Aude Khuong-Josses, Simon Vanveggel, Susan L. Ford, Gary Richmond, Edgar T. Overton, Giuliano Rizzardini, Krischan J Hudson, Amy Cutrell, Susan Swindells, Vasiliki Chounta, Jaime Andrade-Villanueva, Catherine Orrell, Herta Crauwels, David A. Margolis, Mark S. Shaefer, Firaya Nagimova, Yuanyuan Wang, Alexander Wong
Publikováno v:
The Lancet. 396:1994-2005
Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing, and supportive modelling, underpin furthe
Autor:
Saye Khoo, Alistair Paice, Ashini Fox, J. Van Wyk, Achim Schwenk, Matthew Radford, Iain Reeves, Naomi J. Boxall, M Myland, Paul D Benn, A Darley, Adam Croucher, Chinyere Okoli, J Barnes, F Grimson, Stephen Taylor, S Munshi
Publikováno v:
HIV Medicine
Objectives People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug–drug interactions (DDIs) in PWHIV. Methods The Climate‐HIV electronic recording system was used to cross‐sectionally analyse
Autor:
Jaime Andrade-Villanueva, Yuanyuan Wang, Christine L. Talarico, David A. Margolis, Anders Thalme, Veerle Van Eygen, Gary Richmond, Susan L. Ford, Kimberly Y. Smith, Elena Belonosova, Rodica Van Solingen-Ristea, Giuliano Rizzardini, Antonio Ocampo Hermida, Rosie Mngqibisa, Paul D Benn, Herta Crauwels, Krischan J Hudson, Hans Jaeger, William Spreen, Faiza Ajana, Edgar T. Overton, Carlos Martin Espanol, Simon Vanveggel
Publikováno v:
The lancet. HIV. 8(11)
Summary Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting cabo
Autor:
Paul D Benn, Tristan Barber
Publikováno v:
Current Opinion in HIV and AIDS. 5:322-326
PURPOSE OF REVIEW Postexposure prophylaxis (PEP) has become an important part of combined approaches to the prevention of onward HIV transmission. As PEP becomes more widely available after sexual as well as occupational exposure, there are ongoing d
Publikováno v:
Lancet (London, England). 357(9257)
Summary Evidence suggests that nevirapine, a non-nucleoside reversetranscriptase inhibitor, might be very effective in the prevention of HIV-1 integration and the reduction of risk of HIV-1 acquisition after exposure. We used a triple combination reg